ARTICLE INFORMATION

Authors’ Affiliations: Stanford University School of Medicine, Palo Alto (KP); Department of Family Medicine and Public Health, University of California San Diego, San Diego (CAMA); and Divisions of Cardiovascular Medicine (SJ) and Nephrology (MEM-R, TIC), Stanford University School of Medicine, Palo Alto, CA.

Address for Correspondence: Tara I. Chang, MD, MS, Stanford University Division of Nephrology, 777 Welch Rd, Ste DE, Palo Alto, CA 94304. E-mail: tichang@stanford.edu

Authors’ Contributions: Research idea and study design: KP, MEM-R, TIC; data acquisition: TIC; data analysis/interpretation: KP, MEM-R, TIC; statistical analysis: MEM-R, TIC; supervision or mentorship: TIC. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: None.

Financial Disclosure: Dr Chang reports receiving consulting fees from Janssen, Novo Nordisk, and Fresenius for work unrelated to the current project. The remaining authors declare that they have no relevant financial interests.

Disclaimer: AASK was conducted by the AASK Investigators and supported by the NIDDK. The data from AASK reported here were supplied by the NIDDK Central Repositories. This manuscript was not prepared in collaboration with investigators of AASK and does not necessarily reflect the opinions or views of AASK, the NIDDK Central Repositories, or the NIDDK.

Peer Review: Received July 12, 2019. Evaluated by 1 external peer reviewer, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form October 18, 2019.

Publication Information: © 2019 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Published online December 16, 2019 with doi 10.1016/j.kxme.2019.10.008

REFERENCES

1. O’Donnell M, Mente A, Rangarajan S, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371:612-623.
2. Stolarz-Skrzypek K, Kuznetsova T, Thjøs L, et al. Fatal and nonfatal outcomes, incidence of hypertension, and blood pressure changes in relation to urinary sodium excretion. JAMA. 2011;305:1777-1785.
3. Thomas MC, Moran J, Forsblom C, et al. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861-866.
4. Cobb LK, Anderson CAM, Elliott P, et al. Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation. 2014;129(10):1173-1186.
5. Cianciaruso B, Bellizzi V, Minutolo R, et al. Salt intake and renal outcome in patients with progressive renal disease. Miner Electrolyte Metab. 1998;24:296-301.
6. McMahon EJ, Bauer JD, Hawley CM, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24:2096-2103.
7. Smyth A, Dunkler D, Gao P, et al. The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. Kidney Int. 2014;86(6):1205-1212.
8. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol. 2012;23:165-173.
9. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
10. Mills KT, Chen J, Yang W, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA. 2016;315:2200-2210.
11. Liu S, Stedman M. A SAS Macro for Covariate Specification in Linear, Logistic, and Survival Regression: Paper 1223-2017. Proceedings of the SAS Global 2017 Conference. Cary, NC: SAS Institute Inc; 2017.

Physician Attitudes on Kidney Biopsies for Research: A Survey Study

To the Editor:

Kidney biopsy is the gold standard for diagnosing many kidney diseases, but only a minute fraction of patients undergoes this invasive procedure.1 Severe bleeding is a major complication associated with biopsy.2,3 Recent interest in kidney biopsies for research purposes has raised the question of safety for participants.4 To understand how physicians perceive the risks of kidney biopsy, we sent an institutional review board–approved anonymous online survey to 60 hospitalists at 1 academic hospital in Boston and 98 nephrologists at 3 academic hospitals in Boston. Survey participants were asked about their clinical experience, their perceived risk of kidney biopsies, and the likelihood that they would support biopsies being obtained from their patients for research purposes.

The overall response rate was 46% (15/60 hospitalists and 57/98 nephrologists). Twenty-nine (51%) nephrologists and mixed clinical, research, and administrative roles. Twelve (21%) identified as clinicians, and 16 (28%), as researchers. Twenty-eight (47%) were in practice for more than 10 years. All but 1 of the hospitalists had a patient who had undergone a kidney biopsy in the previous 5 years. Three (5%) nephrologists had never done a biopsy, 12 (21%) had performed 10 or fewer, 25 (44%) had performed 11 to 50, and 17 (30%) had performed more than 50 biopsies.

Participants were asked to estimate the likelihood of a variety of postbiopsy complications, including hematoma formation, need for transfusion, need for angiographic or surgical intervention, kidney loss, and death (Table 1). Hospitalists were more likely to underestimate the risk for hematoma complicating a biopsy compared with nephrologists. There were no significant differences between respondents’ assessments of kidney biopsy risk when comparing researchers versus clinicians or stratifying by years of experience or number of biopsies performed. The current literature suggests that the risks for hematoma,
Table 1. Willingness of Nephrologists to Allow Their Patients to be Approached for a Study Involving Research Kidney Biopsies

| Scenarios                                                                 | Primarily Clinical Care (n = 12) | Primarily Research and Administration (n = 43) | P     |
|--------------------------------------------------------------------------|----------------------------------|-----------------------------------------------|-------|
| Reserve a small portion of an existing core                              | 4.7 (0.6)                        | 4.7 (0.5)                                      | 0.97  |
| Perform an extra pass to obtain a research core                          | 2.3 (1.3)                        | 3.3 (1.2)                                      | 0.02  |
| For research biopsies                                                    |                                  |                                               |       |
| Acute kidney injury with clinical equipoise                              |                                  |                                               |       |
| Suspected AIN from nafcillin vs ATN from hypotension                     | 2.6 (1.2)                        | 3.6 (1.1)                                      | 0.01  |
| Suspected CIN vs atheroemboli post–cardiac catheterization              | 2.6 (1.2)                        | 3.2 (1.0)                                      | 0.12  |
| Suspected ATN vs AIN post–cardiac surgery                               | 2.8 (1.3)                        | 3.4 (1.0)                                      | 0.09  |
| Acute kidney injury without clinical equipoise                            |                                  |                                               |       |
| Clinical diagnosis of AIN from nafcillin                                 | 2.1 (0.9)                        | 3.1 (1.2)                                      | 0.007 |
| Suspected CIN post–cardiac catheterization                              | 2.1 (1.0)                        | 2.6 (1.1)                                      | 0.18  |
| Suspected ATN post–cardiac surgery                                       | 1.9 (0.9)                        | 2.6 (1.2)                                      | 0.09  |
| CKD                                                                       |                                  |                                               |       |
| Nonproteinuric CKD stage 3                                               | 2.4 (1.0)                        | 3.2 (1.2)                                      | 0.04  |
| CKD stage 3 suspected to be due to diabetes                              | 2.3 (1.2)                        | 3.3 (1.2)                                      | 0.01  |
| Average score on Likert scale                                           | 2.6 (0.9)                        | 3.3 (0.8)                                      | 0.008 |

Note: Results are reported as mean (standard deviation) on a scale of 1 through 5 (higher number suggests higher likelihood).

Abbreviations: AIN, acute interstitial nephritis; ATN, acute tubular necrosis; CIN, chronic interstitial nephritis; CKD, chronic kidney disease.

transfusion, need for invasive procedure to achieve hemostasis, and death are >20%, 2% to 5%, 1%, and <0.1%, respectively.\(^2\) Overall, participants underestimated the risks for hemotoma (only 8 of 72 responded >10%) and transfusion (only 11 of 72 responded >1%). Respondents were asked to grade the likelihood of agreeing to a research kidney biopsy in a variety of clinical scenarios: (1) reserving portions of a core in clinically indicated biopsies; (2) performing an extra pass in clinically indicated biopsies; and (3) performing research biopsies in patients with no indication. Respondents self-identified their roles and were categorized into 2 groups, primarily clinical care or mix of clinical, research, and administration (Item S1). We scored responses using a Likert scale (1 = “absolutely not”; 5 = “definitely yes”). We used Kruskall-Wallis with a single group factor (research vs clinical) predicting mean differences in scores between groups. In patients undergoing biopsy as part of their clinical care, 71 (98%) respondents answered “likely” or “definitely yes” to the question of whether they would agree to a portion of the core being reserved for research, and 24 (34%) reported that they would be “unlikely” or would “absolutely not” allow an extra pass to be performed to obtain a research core. For biopsies obtained primarily for research purposes, participants’ responses varied depending on the likelihood that clinically useful information might be found from the biopsy.

Interestingly, we observed that there was a difference in responses between nephrologists who were involved in research compared with those who were primarily clinicians. In every scenario, a lower proportion of clinicians were comfortable with allowing a research kidney biopsy compared with researchers (Table 1). For example, primarily research nephrologists were more willing to support an extra needle pass during clinically indicated kidney biopsies to obtain a research core as well as to perform a biopsy in a patient with chronic kidney disease stage 3 suspected to be due to diabetes. The overall mean score on the Likert scale across all scenarios was lower in the clinical nephrologists compared with the researchers (2.6 ± 0.9 vs 3.3 ± 0.8, respectively; P = 0.008).

Our results provide some perspective on physician attitudes toward kidney biopsies, which has not been an area of significant investigation to our knowledge. There are several limitations to consider. Most importantly, our sample size was relatively small and drew from physicians at academic hospitals in a single city in the Northeast United States. The lower response rate among hospitalists was likely because they are less likely to make decisions regarding the suitability of biopsies and would defer to nephrologists. Larger studies that include different regions and community practices would provide more generalizability. We limited our questions to brief descriptions of cases without the opportunity for more additional detail to be provided on the clinical context. Cases were designed to test the likelihood of allowing a biopsy in situations in which the clinical indication is not clear cut and so cannot speak to physicians’ overall confidence in kidney biopsy as a procedure. We did not query patients about their perceptions of the risks and benefits of kidney biopsy. This represents an area in need of further investigation.

In conclusion, kidney biopsies for research purposes are beginning to be performed to enhance our understanding of the underlying mechanisms contributing to kidney disease. Engaging physicians and the broader community will require ongoing education, as well as transparency about the risks and benefits of kidney biopsy.

Gearoid M. McMahon, MB BCh, Afolarin Amodu, MBBS, Meghan E. Sise, MD, Suraj Sarvode Mothi, MPH Ragnar Palsson, MD, Sushrut S. Waikar, MD, MPH

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Item S1: Physician Survey for Research Kidney Biopsies
ARTICLE INFORMATION

Authors’ Affiliations: Renal Division, Brigham and Women’s Hospital (GMM, AA, SSM, RP, SSW); Harvard Medical School (GMM, AA, MES, SSM, RP, SSW); Renal Division, Massachusetts General Hospital (MES); and Renal Section, Department of Medicine, Boston University Medical Center, Boston, MA (AA, SSW).

Address for Correspondence: Sushrut S. Waikar, MD, MPH, Renal Section, Department of Medicine, Boston University Medical Center, 72 E Concord St, Boston, MA 02118. E-mail: swaikar@bu.edu

Authors’ Contributions: Research idea and study design: SW, MS; data acquisition: SW; data analysis/interpretation: GMM, AA, SSM, RP; statistical analysis: GMM, AA, SSM; supervision or mentorship: SW. Each author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

Support: None.

Financial Disclosure: The authors declare that they have no relevant financial interests.

Peer Review: Received June 28, 2019. Evaluated by 1 external peer reviewer, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form October 18, 2019.

Publication Information: © 2019 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Published online December 16, 2019 with doi 10.1016/j.xkme.2019.10.009

REFERENCES

1. Fiorentino M, Bolignano D, Tesar V, et al. Renal biopsy in 2015— from epidemiology to evidence-based indications. Am J Nephrol. 2016;43(1):1-19.
2. Corapi KM, Chen JL, Balk EM, Gordon CE. Bleeding complications of native kidney biopsy: a systematic review and meta-analysis. Am J Kidney Dis. 2012;60(1):62-73.
3. Korbet SM, Volpini KC, Whittier WL. Percutaneous renal biopsy of native kidneys: a single-center experience of 1,055 biopsies. Am J Nephrol. 2014;39(2):153-162.
4. Waikar SS, McMahon GM. Expanding the role for kidney biopsies in acute kidney injury. Semin Nephrol. 2018;38(1):12-20.
5. Whittier WL, Sayeed K, Korbet SM. Clinical factors influencing the decision to transfuse after percutaneous native kidney biopsy. Clin Kidney J. 2016;9(1):102-107.